Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Intramuscular Ketamine Administration for the Treatment of Acute Suicidal Ideation With Concurrent EEG Monitoring

To see complete record on, please visit this link

Id: NCT05105061

Organisation Name: Icahn School of Medicine at Mount Sinai

Overal Status: Withdrawn

Start Date: February 2022

Last Update: April 5, 2022

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary: The objective of the present research protocol, a cross-over, subject-blinded, clinical trial, is to correlate changes in brain activity with reduction in suicidal ideation in response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal properties that may be distinct from its effects on depression. This pilot study will be used to determine (1) whether specific electroencephalogram (EEG) findings are correlated with response of SI to intramuscular (IM) ketamine, and (2) the effectiveness of IM ketamine in the treatment of acute SI.

  • Suicidal Ideation

Total execution time in seconds: 0.21018099784851